Immunome Filed Misleading Prospectus Ahead of Merger, Suit Says

Immunome Inc. allegedly misrepresented or omitted information from a prospectus ahead of its proposed merger with Morphimmune Inc., a shareholder suit filed Friday says.

The biopharmaceutical companies agreed to the merger terms in June, which would convert Morphimunne common stock to Immunome shares at a rate of .3042 per share, but then issued a false prospectus that allegedly violated the Exchange Act in August, according to the complaint filed in US District Court for the District of Delaware.

Shareholders can’t vote to approve without the material information that was Immunome and its directors allegedly omitted from the prospectus, including ...